Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Q2 2018 Earnings Presentation
16 slides from Trendlines's earnings presentation, Aug 7, 2018
Slide 1: The Trendlines Group Financial Highlights Q2 2018
The Trendlines Group Financial Highlights Q2 2018 Steve Rhodes Todd Dollinger Haim Brosh Chairman and CEO Chairman and CEO Chief Financial Officer August 2018 SGX:42T OTCQX: TRNLY
Slide 2: Agenda
Agenda • Corporate highlights • Financial highlights • Post Q2 2018 developments 2
Slide 3: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 4: Corporate highlights
Corporate highlights
Slide 5: 10 years of portfolio value expansion
10 years of portfolio value expansion US$ millions Portfolio value with exit proceeds 140 120 Portfolio value* 100 Cumulative exit proceeds 80 60 40 20 0 30.12.08 30.12.09 30.12.10 30.12.11 31.12.12 31.12.13 31.12.14 31.12.15 31.12.16 31.12.17 30.6.18 *Portfolio value includes the fair value of inve
Slide 6: Key financial developments Q2 2018
Key financial developments Q2 2018 30 June 2018 31 December 2017 Change % Change Portfolio value US$ 96.2 million US$ 96.8 million - US$ 0.6 million not material Book value US$ 89.6 million US$ 92.9 million - US$ 3.3 million -4% Current assets US$ 15.6 million US$ 20.4 million - US$ 4.8 million -24%
Slide 7: Q2 2018 developments
Q2 2018 developments • B. Braun Medical SAS, acquirer of Stimatix GI Ltd.’s assets, confirmed product launch remains on track for 2018. • Trendlines Incubators Israel Ltd. and Sirius Venture Capital e Participacoes Ltda signed an investment cooperation agreement. • Portfolio company Arcuro Ltd. anno
Slide 8: 10 companies (+1) to watch
10 companies (+1) to watch* • ApiFix Ltd. • Leviticus Cardio Ltd. • BioFishency Ltd. • MemTech Ltd. • EdenShield Ltd. • Saturas Ltd. • Fidmi Medical Ltd. • STS Medical Ltd. • Gordian Surgical Ltd. • Vensica Medical Ltd. +1 Stimatix GI Ltd. *Updated report issued: 26 July 2018 8
Slide 9: Q2 highlights from the "10 Companies to Watch" report
Q2 highlights from the “10 Companies to Watch” report • ApiFix Ltd. and Gordian Surgical Ltd. completed >230 surgeries • BioFishency Ltd. reached ~US$1 million in sales in H1 2018 • STS Medical Ltd. successfully implanted and removed first stents in Lenox Hill Hospital, New York • EdenShield Ltd. in
Slide 10: Financial highlights
Financial highlights
Slide 11: Consolidated condensed report of income
Consolidated condensed report of income 11
Slide 12: Key value components
Key value components Change in portfolio value during quarter Balance sheet (US$ millions) 15.6 (3.5) (3.8) 2.1 (2.7) (13.9) (1) 96.8 96.2 89.6 Net portfolio Investments Fair value Net portfolio Cash, short- Fair value of Deferred Deferred tax** Payables & Total equity value 31.12.17 and new decreas
Slide 13: Post Q2 2018 developments
Post Q2 2018 developments
Slide 14: Post Q2 2018 developments
Post Q2 2018 developments • Following MOU signed with Nutreco Investments B.V. in Q1 2018, portfolio company ViAqua Therapeutics Ltd. announced investment by Nutreco. • OrthoSpin Ltd. announced that Johnson & Johnson Innovation – JJDC, Inc. led a US$3 million investment round. • One new agtech compa
Slide 15: SGX: 42T OTCQX: TRNLY www.trendlines.com
SGX: 42T Steve Rhodes, Chairman & CEO OTCQX: TRNLY steve@trendlines.com Todd Dollinger, Chairman & CEO +972.72.260.7000 todd@trendlines.com www.trendlines.com Haim Brosh, Chief Financial Officer haim@trendlines.com 7 August 2018
Slide 16: SGX announcement: Financial Statements and Related Announcement
Issuer/Manager THE TRENDLINES GROUP LTD. Securities THE TRENDLINES GROUP LTD. – IL0011328858 – 42T Stapled Security No Announcement Title Financial Statements and Related Announcement Date & Time of Broadcast 07-Aug-2018 17:56:35 Status New Announcement Sub Title Second Quarter and/ or Half Yearly R